Novartis to buy U.S.-based biotech CoStim for undisclosed price

ZURICH (Reuters) - Novartis said it will buy U.S.-based CoStim Pharmaceuticals Inc., a privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer, for an undisclosed price.

The Swiss drugmaker said the move follows increasing evidence pointing to the role of the immune system in controlling cancer.